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Abstract: 
Central injections of Pituitary adenylate cyclase-activating polypeptide 
(PACAP) into the ventromedial nuclei (VMN) of the hypothalamus produce 
hypophagia that is dependent upon the PAC1 receptor, however, the signaling 
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downstream of this receptor in the VMN is unknown. Though PACAP signaling 
has many targets, this neuropeptide has been shown to influence glutamate 
signaling in several brain regions through mechanisms involving NMDA 
receptor potentiation via activation of the Src family of protein tyrosine 
kinases. With this in mind, we examined the Src-NMDA receptor signaling 
pathway as a target for PACAP signaling in the VMN that may mediate its 
effects on feeding behavior. Under nocturnal feeding conditions, NMDA 
receptor antagonism prior to PACAP administration into the VMN attenuated 
PACAP-mediated decreases in feeding suggesting glutamatergic signaling via 
NMDA receptors is necessary for PACAP-induced hypophagia. Furthermore, 
PACAP administration into the VMN resulted in increased tyrosine 
phosphorylation of the GluN2B subunit of the NMDA receptor, and inhibition of 
Src kinase activity also blocked the effects of PACAP administration into the 
VMN on feeding behavior. These results indicate that PACAP 
neurotransmission in the VMN likely augments glutamate signaling by 
potentiating NMDA receptors activity through tyrosine phosphorylation events 
mediated by the Src kinase family, and modulation of NMDA receptor activity 
by PACAP in the hypothalamus may be a primary mechanism for its regulation 
of food intake.  
Keywords: feeding, VMN, glutamate, Src kinase, PACAP. 
Introduction 
 Hypothalamic glutamate neurotransmission is crucial to energy 
balance [1-6], in part, through the regulation of feeding behavior [7-
9]. This is in contrast to classical views of hypothalamic signaling that 
have focused on the importance of neuropeptides for homeostatic 
regulation. However, recent investigations into mechanisms of 
neuropeptide function have indicated that modulation of the fast-
acting amino acid neurotransmitters, glutamate and GABA, may be a 
primary role for neuropeptide signaling [10]. For example, the 
neuropeptides orexin and neuropeptide Y (NPY) both potently increase 
feeding behavior through glutamate receptor-dependent signaling 
pathways in the lateral hypothalamus [11, 12] and that orexin causes 
enhancement of presynaptic glutamate release and postsynaptic NMDA 
receptor activity in the ventral tegmental area [13].  
 The hypothalamic ventromedial nuclei (VMN) are critical 
regulators of body weight and possess both high levels of glutamate 
and all glutamate receptor subtypes [4, 14-16]. Stimulation of these 
nuclei produces reductions in food intake and increased metabolic rate 
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[8, 17-20]. Likewise, microinjection of the pleiotropic neuropeptide 
pituitary adenylate cyclase-activating polypeptide (PACAP) into the 
VMN inhibits feeding behavior through activation of PAC1 receptors 
even after food deprivation [21, 22], however, the VMN neuronal 
signaling downstream of PAC1R leading to decreased food intake is 
currently unknown. However, previous demonstration of synergy 
between PACAP and glutamate [23-25] in other brain regions suggests 
that PACAP-PAC1R signaling in the VMN may lead to augmented 
glutamate neurotransmission.  
 Co-localization of PACAP and glutamate immunoreactivity in 
retinal ganglion cells, as well as in nerve terminals located in the 
suprachiasmatic nuclei (SCN) support a mechanism of co-release at 
synapses of the retinohypothalamic tract [23, 26, 27]. Functionally, 
PACAP application to SCN slices produces dose-dependent phase shifts 
in circadian rhythms through modulation of NMDA receptor activity 
[24]. In another brain region, PACAP enhances NMDA receptor activity 
in the hippocampus, reportedly by two separate mechanisms involving 
Src tyrosine kinase signaling. The first of which involves cAMP/PKA-
dependent activation of Fyn, a member of the Src tyrosine kinase 
family, leading to phosphorylation of multiple tyrosine residues on the 
GluN2B subunit of the NMDA receptor [28], while the second was 
shown to occur via PAC1R activation of a phospholipase C pathway 
leading to Src tyrosine kinase activation and augmented hippocampal 
NMDA receptor function [25]. Both PACAP-mediated signaling 
pathways reported in the hippocampus suggest that modulation of 
NMDA receptors can occur through Src family kinase activity, which 
has been implicated in the regulation of feeding behavior by lateral 
hypothalamic neurons [29]. 
 In order to determine whether modulation of glutamatergic 
NMDA receptor signaling underlies the regulation of feeding behavior 
by PACAP in the hypothalamus we measured nocturnal food intake 
following pharmacological inhibition of NMDA receptor function within 
the VMN prior to PACAP injection. Moreover, we analyzed tyrosine 
phosphorylation of NMDA receptors following PACAP administration 
and examined whether activity of Src family kinases is important for 
PACAP-mediated alterations of feeding behavior in the VMN. Our 
results suggest that NMDA receptor activity is necessary for PACAP-
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induced hypophagia in the VMN, and PACAP may act through 
stimulation of Src kinases to augment NMDA receptors function.    
Methods 
Animals 
Male Sprague-Dawley rats (Harlan; Madison, WI) weighing 225-
250 g were individually housed in a climate controlled room with a 12 
hr light/dark cycle. Animals had free access to Harlan standard diet 
(8604 formulation) and water. Food consumption was measured with a 
BioDAQ Food Intake Monitor (Research Diets; New Brunswick, NJ) or 
calculated by pre-weighing food in each bin and subtracting the weight 
of non-ingested and spilled food at the end of each measurement 
period. All procedures using animals were approved by the Marquette 
University Institutional Animal Care and Use Committee. 
Surgery   
Animals were anesthetized with a ketamine/xylazine/acepromazine 
(77:1.5:1.5 mg/ml/kg; ip) cocktail and placed in a stereotaxic 
apparatus. Bilateral guide cannulae (26 gauge; Plastics One; Roanoke 
VA) were placed 3 mm dorsal to the target site in all animals, and 
secured to the surface of the skull with an acrylic resin. The 
stereotaxic coordinates for the VMN were anterior/posterior, -2.5 mm 
from bregma; medial/lateral, 0.6 mm from midline; dorsal/ventral, -
6.2 mm from surface of the skull based on The Rat Brain in Stereotaxic 
Coordinates, 6th Edition [30]. Injectors extended 3 mm past the 
ventral tip of the cannulae reaching a VMN injection site of -9.2 mm 
ventral from the surface of the skull. The upper incisor bar was 
positioned -3.3 mm below horizontal zero. A bilateral dummy stylet 
placed in the guide cannulae was used to maintain patency. All 
animals were given at least five days to recover after cannula 
installation before receiving drug or vehicle injections, during which 
time the animals were handled and dummy stylets were removed and 
replaced daily in order to acclimate the animals to the physical 
handling necessary during experiments. Correct cannulae placements 
were confirmed at the conclusion of each experiment by microscopic 
examination of Nissl stained sections and only those with correct 
placement were included in the studies. 
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Feeding Behavior Experiments 
Animals were weighed daily and acclimated to the BioDAQ Food 
Intake Monitor for at least 7 days before the onset of the experiment. 
In all experiments, approximately 1 hour prior to lights off rats 
received bilateral microinjections of vehicle, D-(-)-2-amino-5-
phosphonopentanoic acid (AP5; 10 pmol - 1 nmol in saline/0.25 
µl/side; Tocris Bioscience), or 1-(1,1-Dimethylethyl)-1-(4-
methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (PP1; Src kinase 
inhibitor; 1 - 100 pmol in 10 % DMSO/0.25 µl/side; 1 nmol in 25% 
DMSO/0.25 µl/side; Tocris Bioscience) over approximately two minutes 
in awake animals while gently restrained. When necessary, DMSO was 
used as a vehicle for water insoluble substances such as PP1, as it has 
been previously verified to be suitable for such feeding experiments, 
causing no significant alterations in food intake when administered 
alone, even with solutions at concentrations as high as 75% [29, 31]. 
Upon completion of antagonist/inhibitor injections an additional minute 
elapsed before removing injectors to minimize backflow of injected 
material. Five minutes later (15 minutes for PP1 studies) rats received 
a second bilateral injection of either saline or PACAP (50 pmol/0.25 
µl/side; PACAP38; California Peptide Research; Napa, CA) and upon 
completion animals were returned to their home cage for subsequent 
feeding measurements. The optimal injection volume of 0.25 µl to 
contain microinjections within VMN was determined previously [21]. 
Feeding measurements were collected for the next 24 hours, with the 
greatest emphasis placed on the first 3-5 hours after microinjections 
were delivered.  
 
Western blot analysis of GluN2B tyrosine 
phosphorylation   
 Thirty minutes following saline or PACAP (50 pmol/0.25 µl/side) 
injections into the VMN, bilateral dissections of the ventromedial 
hypothalamus (VMH; including the VMN and surrounding areas) were 
collected. VMH tissue was homogenized by hand (10 strokes) in ice-
cold homogenization buffer (320 mM sucrose, 10 mM Tris-HCl, pH 7.4, 
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10mM EDTA, 10mM EGTA) containing Halt protease and phosphatase 
inhibitor cocktail (Pierce; Rockfork, IL), followed by 3-4 seconds of 
sonication. Homogenates were centrifuged at 1000 X g for 2 minutes 
at 4° C to remove nuclei and large debris. The resulting supernatant 
was further centrifuged at 10,000 X g for 30 minutes at 4° C to obtain 
a crude membranal pellet that was resuspended in solubilization buffer 
(1% Triton x-100, 150 mM NaCl, 10nM Tris-HCl pH 7.4, 1 mM EDTA, 1 
mM EGT, protease & phosphatase inhibitor cocktail). Protein 
quantification of samples was determined using a bicinchoninic (BCA) 
assay (Pierce). Membrane protein (20 µg) was run on an 8% gel by 
SDS-PAGE and transferred to a polyvinylidine fluoride (PVDF) 
membrane. Membranes were blocked with 5% bovine serum albumin 
(BSA) in tris-buffered saline containing 0.1 % Tween-20 (TBS-T). Blots 
were then probed with rabbit anti-pY1336 GluN2B antibody (Rockland 
Immunochemicals; Gilbertsville, PA) overnight at 4° C, followed by 
washes with TBS-T and incubation with an HRP-conjugated mouse 
anti-rabbit secondary antibody (Jackson Immunoresearch; West 
Grove, PA) at room temperature for 2 hours. Band intensities for 
pY1336 were developed using SuperSignal West Femto 
chemiluminescent substrate (Pierce) and visualized using the Kodak 
Image Station 4000MM. After visualization of pY1336 signal, blots 
were stripped and reprobed in an identical fashion for total GluN2B 
expression using mouse anti-GluN2B (Rockland Immunochemicals) 
and HRP-conjugated goat anti-mouse (Jackson Immunoresearch) 
antibodies. Band densities were measured using Kodak Molecular 
Imaging Software v4.0. 
Statistics 
Data are presented as means ± standard errors of the mean, 
and were analyzed statistically by analysis of variance (with repeated 
measures when appropriate). Fischer LSD analysis was used for all 
post-hoc group comparisons. Statistical analyses were performed 
using Sigma Plot 11 software (Systat Software Inc.; San Jose, CA). P 
< 0.05 were considered statistically significant. 
Results  
  Our previous efforts to characterize the effects of PACAP 
signaling in the hypothalamus have demonstrated a PAC1R-dependent 
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decrease in food intake following site-specific injections into the VMN 
[21, 22]. Considering previous associations between PACAP and NMDA 
receptor signaling [24, 25, 28, 32], as well as the potential of NMDA 
receptor activity to regulate feeding behavior [11, 12, 29, 33], we 
proceeded to test whether glutamate signaling via the NMDA receptor 
was necessary for PACAP-mediated reductions in food intake. Initially, 
the NMDA receptor antagonist AP5 was administered bilaterally into 
the VMN at multiple doses ranging from 10 pmol to 1 nmol to 
investigate its contribution to normal nocturnal feeding behavior. 
Surprisingly, none of the three doses tested significantly altered 
feeding behavior (Fig. 7.4A). To determine whether NMDA receptor 
function is necessary for PACAP-mediated decreased food intake, 
animals received AP5 (10 pmol/side) injections into the VMN prior to 
PACAP (50 pmol/side). Although AP5 treatment alone again had no 
effect on feeding, it did successfully block the effects of PACAP 
injections into the VMN on food intake (Fig. 7.4B; P < 0.05).  
 With the evidence that NMDA receptor function appears to be 
necessary for decreased food intake induced by PACAP, we examined 
whether similar mechanisms of NMDA receptor potentiation by PACAP 
existed within the hypothalamus as has been reported in the 
hippocampus [25, 28]. PACAP treatment of hippocampal slices was 
found to produce increased phosphorylation of tyrosines 1252, 1336, 
and 1472 specifically on the GluN2B subunit of NMDA receptors [28], 
therefore to test for tyrosine phosphorylation under our conditions we 
performed microinjections of saline or PACAP in a similar manner prior 
to feeding experiments but collected VMH tissue 30 minutes post-
injection for GluN2B tyrosine phosphorylation analysis. In western 
blotting experiments we examined phosphorylation levels of tyrosine 
1336 (pY1336) on the GluN2B subunit of the NMDA receptor and 
normalized band intensities to total GluN2B expression. Indeed, semi-
quantitative analysis demonstrated that VMN PACAP treatment 
increased pY1336 expression by approximately 25% (Fig. 7.5A & B; P 
< 0.05).  
  Tyrosine phosphorylation of the NMDA receptor mediated by 
PACAP signaling has been associated with increased Src family kinase 
activity [25, 28], which has also been implicated in the regulation of 
feeding behavior by the lateral hypothalamus [29].  Supported by the 
studies conducted in the hippocampus [28] as well as the data 
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presented here, the phosphorylation appears to be specific to the 
GluN2B subunit of the NMDA receptor. Taken together it is probable 
that PACAP-PAC1R signaling results in tyrosine phosphorylation of the 
GluN2B subunit of the NMDA receptor in the VMN through activation of 
an Src kinase. To confirm this possibility the Src kinase inhibitor PP1 
(1 - 1000 pmol/0.25 µl/side) was injected into the VMN followed by 
measurements of food intake. No concentration of PP1 used in these 
studies significantly altered food intake when injected into the VMN 
alone (Fig. 7.6A). However, pretreatment with PP1 (10 pmol/side) in 
the VMN prior to PACAP injections did significantly attenuate the 
hypophagic effects of PACAP (Fig. 7.6B; P < 0.05). 
 Discussion 
 By inhibiting NMDA receptor signaling we were able to examine 
the contribution of its activity to PACAP-mediated decreases in food 
intake in the VMN. Pretreatment with the NMDA receptor antagonist 
AP5 successfully attenuated the hypophagic response to PACAP 
administration into the VMN. These data build upon previous findings 
indicating that PACAP-PAC1R signaling may potentiate postsynaptic 
NMDA receptor activity (Figure 4) [24, 25, 32], perhaps through 
phosphorylation of the GluN2B subunit [28]. Upon examination of 
GluN2B phosphorylation following PACAP injections into the VMN in 
vivo, we detected an increase in phosphorylation at tyrosine 1336, a 
previously identified site of PACAP-induced tyrosine phosphorylation on 
the GluN2B subunit of the NMDA receptor [28]. Not only has the Src 
family of non-receptor tyrosine kinases been previously described to 
facilitate NMDA receptor phosphorylation mediated by PACAP [25, 28], 
but hypothalamic Src activity has been demonstrated to play a role in 
the regulation of feeding behavior [29]. These findings led us to test 
whether Src was a downstream mediator of PACAP-induced 
hypophagia in the VMN. Inhibition of Src family tyrosine kinases with 
PP1 effectively blocked the effects of intra-VMN PACAP on feeding 
behavior, thus supporting a mechanism for PACAP-mediated 
potentiation of NMDA receptors via an Src-dependent pathway.    
 Similar to our current data combining NMDA receptor 
antagonists with PACAP injections into the VMN, inhibition of NMDA 
receptors also blocks hyperphagia induced by orexin and neuropeptide 
Y in the lateral hypothalamus as well as refeeding following a fast [11, 
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12]. In contrast, AMPA/kainate and NMDA glutamate receptor agonists 
produce robust feeding in sated rats when administered into the lateral 
hypothalamus [7, 33, 34]. Although treatment with AP5 in the VMN did 
not produce increased feeding behavior as one might expect, AP5 was 
administered at a time when feeding behavior was naturally at its 
peak, possibly reducing our ability to detect AP5-induced alterations in 
feeding behavior. However, our current findings indicate that VMN 
PACAP injections produce NMDAR-dependent hypophagia and GluN2B 
tyrosine phosphorylation, and that NMDA receptors in the VMN 
significantly regulate feeding behavior. In the lateral hypothalamus, 
antagonism of GluN2B containing NMDA receptors with ifenprodil 
attenuates the feeding response to both fasting and microinjection of 
NMDA into the lateral hypothalamus, although ifenprodil 
concentrations used in these studies may have also antagonized 
GluN2A containing NMDA receptors [36]. The phosphorylation state of 
the GluN2B subunit may be critical for augmenting NMDA receptor 
activity induced by PACAP signaling, and appears to be regulated by 
the Src family of tyrosine kinases [25, 28], a family of kinases that is 
critical to the function and signaling of NMDA receptors also reported 
to reduce GluN3A trafficking to the synaptic membrane [37-39]. 
Importantly, inhibition of Src family tyrosine kinases by PP1 has 
previously been reported to block NMDAR-dependent feeding behavior 
in the lateral hypothalamus [29], similar to our data regarding PACAP 
signaling in the VMN.  
 Although our investigations of PACAP-mediated feeding behavior 
in the VMN cannot directly demonstrate potentiation of postsynaptic 
NMDA receptors by PACAP signaling, extensive biochemical and 
electrophysiological analysis of glutamate signaling in the hippocampus 
has demonstrated this modulatory pathway. PACAP application yields 
enhancement of field excitatory postsynaptic potentials, brain derived 
neurotrophic factor mRNA expression, and tyrosine phosphorylation of 
the GluN2B subunit of the NMDA receptor by Fyn tyrosine kinase, 
which is a member of the Src family of tyrosine kinases [28]. Further 
coupling PACAP to glutamate signaling, PACAP augments NMDA 
currents following Schaffer collateral stimulation through a PAC1R-
dependent pathway that activates Src tyrosine kinase [25]. While two 
different mechanisms of NMDA receptor potentiation by PACAP have 
been identified, both occur as a result of tyrosine phosphorylation of 
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NMDA receptors by a member of the Src family of tyrosine kinases 
(Fyn and Src).   
 PACAP signaling may also modulate other aspects of glutamate 
signaling including the AMPA receptor, as PAC1R-dependent 
potentiation of AMPA receptors at low PACAP concentrations and 
VPAC2R-mediated depression of AMPA receptors at high 
concentrations of PACAP have been reported in the hippocampus [40]. 
Furthermore, excitatory transmission from the basolateral amygdala to 
the central amygdala is augmented through PACAP-VPAC1R increases 
in AMPA receptor activity [41]. However, without further behavioral 
pharmacology examining glutamate receptor-mediated properties of 
PACAP-induced hypophagia in combination with the appropriate 
electrophysiology, the role of other modes of glutamatergic 
neurotransmission cannot be ascertained at this time. Nevertheless, 
our experiments using AP5 and PP1 attenuated the effects of PACAP on 
feeding suggesting a similar mechanism of NMDA receptor modulation 
by PACAP likely exists in the hypothalamus as it does in the 
hippocampus.   
Glutamate is also substantially regulated by astrocytes, which 
are major targets of PACAP signaling [42-44], yielding another 
potentially important mechanism for glutamate modulation by PACAP. 
Astrocytes impact glutamate neurotransmission most notably through 
removal of synaptic glutamate by sodium-dependent excitatory amino 
acid transporters (EAATs) [45-47] and glutamate release from 
astrocytes themselves [48-52]. Given that a single astrocyte can 
interact with numerous synapses [53, 54], their influence over 
glutamate signaling and overall network activity is immense. PACAP is 
already known to increase expression of both GLAST and GLT-1 
(EAAT1 and EAAT2 respectively) in primary cortical astrocyte cultures 
[55], therefore, investigation into how astrocytic glutamate regulation 
is further influenced by PACAP may reveal new insights into signaling 
mechanisms that are important to glutamate homeostasis and may 
influence behavior. Despite the extensive study of how astrocytic 
control of glutamate affects hypothalamic function [6, 56-58] and 
knowledge that PACAP potently regulates feeding behavior [22, 59-
61], whether or not modulation of astrocytic glutamate signaling by 
PACAP influences food intake has yet to be investigated. 
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 The studies described here further our understanding of PACAP 
signaling in the hypothalamus with regard to feeding behavior. 
Previous reports have suggested that PACAP augments NMDA receptor 
activity [24, 25, 28, 32].  In the current study, inhibition of NMDA 
receptor signaling is sufficient to mitigate the hypophagic response to 
PACAP administration in the VMN suggesting a similar relationship 
exists between PACAP and NMDA receptor signaling in the 
hypothalamus. Furthermore, this NMDA receptor modulation by PACAP 
appears to be mediated through Src family kinase signaling, which is 
critical to both NMDA receptor function as well as the regulation of 
feeding behavior [29, 38, 39]. Given the identified pleiotropic actions 
of PACAP, further investigation is warranted to address other 
mechanisms of glutamate modulation by this neuropeptide and how 
such mechanisms are involved in the regulation of feeding behavior.  
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Figure Legends 
Figure 1.  NMDA receptor antagonism attenuates the hypophagic 
effects of PACAP administration into the VMN. (A) Feeding responses 
to a dose-response of bilateral AP5 microinjections into the VMN. (B) 
Bilateral injection of 10 pmol AP5 into the VMN blocks the inhibitory 
effect of PACAP on feeding behavior. Data are expressed as mean  
SEM. * = P < 0.05 compared to control group.  
Figure 2.  PACAP administration into the VMN results in increased 
tyrosine phosphorylation of the GluN2B subunit of the NMDA receptor. 
(A) Representative VMH protein samples from saline or PACAP (50 
pmol/side) microinjections into the VMN probed for phosphorylation of 
tyrosine 1336 of the GluN2b subunit (pY1336) and total GluN2B 
protein expression. (B) Semi-quantitative analysis of band densities for 
pY1336 normalized to total GluN2b expression expressed as a percent 
of saline treatment. Data are expressed as mean  SEM. * = P < 0.05 
Figure 3.  Inhibition of Src kinase activity with PP1 attenuates PACAP-
induced decreases in food intake in the VMN. (A) Feeding response to 
PP1 injections into the VMN. (B) Pretreatment of the VMN with PP1 
prior to PACAP injections prevents PACAP-mediated hypophagia. Data 
are expressed as mean  SEM. * = P < 0.05 compared to control 
group. 
Figure 4.  Modulation of NMDA receptor signaling by PACAP. (A) 
Conventional glutamatergic synapse showing no modulation of 
glutamate neurotransmission leading to lesser excitatory postsynaptic 
potential (EPSP). (B) Proposed potentiation of EPSP following 
modulation of glutamate receptors by PACAP released from glutamate 
and PACAP co-expressing neurons or PACAPergic neurons. 
 
 
